IRMD vs NVCR

For growth investors, IRadimed Corporation (IRMD) is the stronger pick with 14.

4% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). IRadimed Corporation (IRMD) offers the better valuation at 49. 6x trailing P/E (42. 9x forward), making it the more compelling value choice. Analysts rate IRadimed Corporation (IRMD) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, IRadimed Corporation (IRMD) delivered a total return of +214.

1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: IRMD returned +433. 9% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), IRadimed Corporation (IRMD) is the lower-risk stock at 0.

85β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 159% more volatile than IRMD relative to the S&P 500.

By revenue growth (latest reported year), IRadimed Corporation (IRMD) is pulling ahead at 14.

4% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to 16. 7% for IRadimed Corporation. Over a 3-year CAGR, IRMD leads at 16. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IRadimed Corporation (IRMD) is the more profitable company, earning 26.

8% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 26. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRMD leads at 31. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — IRMD leads at 76. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

In this comparison, IRMD (1.

3% yield) pays a dividend. NVCR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, IRadimed Corporation (IRMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

85), 1. 3% yield, +433. 9% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IRMD: +433. 9%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

IRMD pays a dividend while NVCR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.